Description
The abstract explicitly states that mechanisms underlying TLE-HS are not fully understood, yet this represents the most common drug-resistant epilepsy in adults. Understanding these mechanisms is crucial for developing targeted therapies for treatment-resistant patients.
Gap type: open_question Source paper: Hippocampal sclerosis: A review on current research status and its mechanisms. (2025, Ageing research reviews, PMID:40058463)
Resolution criteria
Resolution requires: (1) Whole-exome sequencing or single-cell RNA-seq of surgically resected hippocampal sclerosis tissue from >=40 drug-resistant TLE-HS patients vs. drug-sensitive TLE identifies >=5 somatic mutations or differentially expressed genes (FDR<0.05, >=2-fold) in ion channels, mTOR pathway, or inflammatory pathways specifically enriched in drug-resistant cases; (2) Patient-derived iPSC neurons or organoids from >=4 drug-resistant vs. >=4 drug-sensitive patients show >=2-fold difference in sodium channel inactivation kinetics, GABAergic inhibitory tone (mIPSC frequency/amplitude), or mTOR-S6K1 phosphorylation, providing mechanistic correlate; (3) At least one identified drug-resistance mechanism (e.g., MDR1/P-gp overexpression, Nav1.6 gain-of-function mutation, GABRA1 loss) is validated by knockdown/overexpression rescue in a zebrafish or rodent seizure model with >=30% change in seizure frequency or duration. Histopathological description of hippocampal sclerosis without molecular mechanism data is insufficient.